axitinib extends the lives of advanced kidney cancer sufferers by two months on average , according to trials .
the drug is the latest to face an nhs ban by the rationing watchdog , the national institute for health and clinical excellence -lrb- nice -rrb- .
it has already axed another drug that could be used after treatment stops working and the cancer starts growing again .